Mitoxantrone, Etoposide, and Prednisolone: A Novel Combination in the Treatment of Relapsed and Refractory Lymphoma
January 1990
in “
Leukemia & Lymphoma
”
Studysummary This study reported a 74% overall response rate for a new combination chemotherapy of mitoxantrone, etoposide, and prednisolone in patients with relapsed or refractory Hodgkin's disease or non-Hodgkin's lymphoma.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer